Related Experiment Video
Updated: Jun 24, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Calcium phosphate metabolism and cardiovascular disease in patients with chronic kidney disease
Geoffrey Block1, Friedrich K Port
1Denver Nephrology Associates, Colorado, USA.
Insights
Patients with end-stage renal disease (ESRD) face high cardiovascular mortality due to unique mineral metabolism disorders. Addressing these, including secondary hyperparathyroidism and calcium-phosphorus balance, is crucial for improving outcomes.
Area of Science:
- Nephrology
- Cardiology
- Mineral Metabolism
Background:
- End-stage renal disease (ESRD) patients have 10-100x higher cardiovascular mortality than the general population.
- Traditional cardiovascular disease (CVD) risk factors do not fully explain this disparity.
- Unique mineral metabolism disorders (calcium, phosphorus, PTH, vitamin D) are implicated in ESRD cardiovascular risk.
Purpose of the Study:
- To present evidence on the impact of calcification-induced arterial stiffness on cardiovascular outcomes in ESRD.
- To relate altered mineral metabolism to all-cause and cardiovascular mortality in ESRD.
- To provide management recommendations for mineral metabolism disorders in ESRD.
Main Methods:
- Review of evidence linking mineral metabolism, extraskeletal calcification, and arterial stiffness to cardiovascular outcomes in ESRD.
- Analysis of data relating mineral metabolism abnormalities to mortality in ESRD patients.
Main Results:
- Disorders of mineral metabolism promote extraskeletal calcification and bone remodeling disorders.
- Calcification-induced arterial stiffness significantly impacts cardiovascular outcomes in ESRD.
- Altered mineral metabolism is directly related to increased all-cause and cardiovascular mortality in ESRD.
Conclusions:
- Early intervention for secondary hyperparathyroidism is recommended.
- Judicious vitamin D therapy strategies are advised.
- Careful use of calcium-containing phosphate binders, considering bone and calcium status, is essential.
Abstract:
Traditional risk factors for atherosclerotic cardiovascular disease (CVD) do not adequately explain the considerable increase in cardiovascular mortality observed among patients with end-stage renal disease (ESRD): these patients experience mortality rates 10-100 times those without ESRD. Disorders of mineral metabolism, including abnormalities in calcium, phosphorus, parathyroid hormone, and vitamin D, represent cardiovascular risk factors unique to the ESRD population. These disturbances manifest clinically through the promotion of extraskeletal calcification and disorders of bone remodeling, two processes which appear to share a common pathogenesis. This article presents evidence describing the impact of calcification-induced arterial stiffness on cardiovascular outcomes of patients with ESRD, along with data relating altered mineral metabolism to all-cause and cardiovascular mortality. Specific management recommendations include 1) early intervention to prevent the development of overt secondary hyperparathyroidism, 2) a more judicious strategy for vitamin D therapy, and 3) a thoughtful approach to the use of calcium-containing phosphate binders, taking into account the underlying bone remodeling disorder and the presence or absence of extraskeletal calcium accumulation.
Related Concept Videos
Skeleton and Calcium Homeostasis
Roles of Electrolytes: Calcium and Phosphate
The calcium concentration in blood plasma is primarily regulated...
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management

